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Prevention of Glucocorticoid Induced Osteoporosis
with Alendronate or Alfacalcidol: Relations of Change
in Bone Mineral Density, Bone Markers, and Calcium
Homeostasis
JOHANNES W.G. JACOBS, RON N.J. de NIJS, WILLEM F. LEMS, PIET P.M.M. GEUSENS, ROLAND F.J. LAAN,
ANNE-MARGRIET HUISMAN, ALE ALGRA, ERIK BUSKENS, LORENZ C. HOFBAUER, ANS C.M. OOSTVEEN,
GEORGE A.W. BRUYN, BEN A.C. DIJKMANS, and JOHANNES W.J. BIJLSMA
ABSTRACT. Objective. To explore the relation of changes in measures of bone turnover and changes in bone miner-
al density (BMD) of the lumbar spine and total hip over 18 months in a double-blinded, randomized
trial, comparing the effect of alfacalcidol (101 patients) versus alendronate (100 patients) on BMD in
patients who recently started treatment with glucocorticoids for various rheumatic diseases.
Methods.Associations between changes in serum procollagen type I C-propeptide (P1CP), fasting urine
N-terminal telopeptide of type I collagen (NTx), serum calcium, parathyroid hormone (PTH), osteo-
calcin, and change from baseline in BMD over 18 months were explored with regression and correla-
tion analyses.
Results. In both treatment groups, there was a statistically significant decrease in NTx. In the alfacal-
cidol group there was also a significant increase in P1CP and osteocalcin, in contrast to the alendronate
group, but BMD in the alfacalcidol decreased versus an increase in the alendronate group (p < 0.001).
In neither treatment group were changes in biochemical measures correlated with the change in BMD,
with the exception of a negative correlation in the alendronate group between changes in total hip BMD
and NTx. Use of alendronate resulted in an increased PTH in 27 patients, but the increase in BMD of
these patients was not statistically significantly different compared to patients taking alendronate with
normal PTH levels.
Conclusion. Changes in BMD were not associated with changes in bone measures, with the exception
of NTx in the alendronate group. For the patient taking glucocorticoids in clinical practice, the value of
serial assessment of bone markers is low; changes in markers are no substitute for changes in BMD.
ClinicalTrials.gov number: NCT00138983. (First Release April 1 2007; J Rheumatol 2007;34:1051–7)
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For many rheumatic diseases, glucocorticoids (GC) are one of
the keystones of therapy. One of the major adverse effects is
glucocorticoid-induced osteoporosis (GIOP), especially with
GC dosages of ≥ 7.5 mg prednisolone equivalent daily for at
least 6 months. Bone loss is already initiated early in GC
treatment. In recent decades, several international guidelines
for prevention and therapy of GIOP have been developed1-5.
In general, in these guidelines, apart from calcium and vita-min D3 supplementation, bisphosphonates are recommended
in patients with a high risk of fractures. Alendronate has been
proven to be effective in GIOP6-8.
GIOP is characterized by uncoupling of bone resorption
and formation: bone formation is decreased (by inhibition of
osteoblast proliferation)9 with initial increase of bone resorp-
tion. Bisphosphonates decrease bone resorption and, by the
coupling of bone resorption to bone formation, probably also
bone formation, but with a positive net result on bone miner-
al density (BMD). An important mechanism of inhibition of
bone resorption by bisphosphonates is induction of apoptosis
of osteoclasts10.
Theoretically, for the prevention and therapy of GIOP,
medication that increases bone formation would be more
appropriate than medication that decreases bone resorption.
The mode of action of active vitamin D3 metabolites is main-
ly increased bone formation by direct stimulation of
osteoblasts11, but active vitamin D3 metabolites also inhibit
bone resorption12. Active vitamin D3 has been shown to have
favorable results in the prevention and therapy of GIOP13.
This was the rationale of a double-blind double-dummy mul-
ticenter clinical trial that we performed on the effects and tol-
erance of alendronate versus those of alfacalcidol in the pre-
vention of GIOP in patients with rheumatic diseases, who
recently had been started with GC therapy. The results of the
effects of the medication on BMD have been published
recently14. This study is aimed at exploration of interrelations
of changes in measures of bone turnover, calcium homeosta-
sis, and BMD in the 2 groups taking GC (the alendronate and
the alfacalcidol group) to determine the mode of action of
these therapies for prevention of GIOP and to analyze the pre-
dictive value of changes in markers toward changes in BMD.
MATERIALS AND METHODS
Patients. Patients with a rheumatic disease, in whom GC were started (not
longer than 12 weeks previously) in a dosage of 7.5 mg prednisolone equiv-
alent daily or higher and expected to last for 6 months or longer, were includ-
ed in a randomized, double-blind, double-dummy clinical trial of 18 months’
duration. Patients were allocated to treatment with either alendronate 10 mg
and alfacalcidol-placebo daily or alfacalcidol 1 ﾵg and alendronate-placebo
daily. In case of insufficient dietary calcium intake (based on a questionnaire),
patients received calcium 500 mg daily and, if vitamin D deficiency existed
(serum level < 30 nmol/l), supplementation with plain vitamin D3 400 IU
daily. No other drugs known to influence bone metabolism were used. The
study is described in detail elsewhere14. This study is registered as
ClinicalTrials.gov number NCT00138983.
Methods. For changes in BMD, we used changes from baseline at 18 months
of BMD of the lumbar spine (LS) and of the total hip, measured in g/cm2.
Baseline represented the day of randomization for alendronate or alfacalcidol;
the first urine and blood samples for markers were taken at baseline, before
taking the first dose of alendronate or alfacalcidol. The LS was chosen as pri-
mary BMD variable because of the high content of trabecular bone, which has
a higher bone turnover than in the hip and thus potentially is most sensitive to
change. Another argument to choose the LS as primary BMD variable was
that the hips could be involved in the disease process in the rheumatic patients
included.
In the context of our study, repeated measurements were performed of the
following bone markers: serum procollagen type I C-propeptide (P1CP) as
marker of bone formation, serum osteocalcin as marker of bone turnover, and
fasting urine free deoxypyridinoline (dPyr) and fasting N-terminal telopeptide
of type I collagen (NTx) as markers of bone resorption. In addition, repeated
measurement of serum calcium corrected for serum albumin, serum parathy-
roid hormone (PTH), and serum osteoprotegerin (OPG) was performed. Of
these measurements, performed at different intervals in time, delta area under
the curve values (dAUC), corrected for time, were calculated, “delta” with
respect to baseline. These dAUC values thus are comparable with a global
mean value for change from baseline and, because of the correction for time,
can be interpreted more easily15. Serum for measurement of calcium and
albumin was collected at baseline and at Months 1, 2, 3, 6, 9, 12, 15, and 18.
Calcium was corrected for albumin according to the following method: calci-
um + [(40 – albumin) × 0.02]. In addition, PTH (baseline and Months 1, 2, 3,
and 18; chemiluminescent immunoassay), P1CP (baseline and Months 6, 12,
18; radioimmunoassay) and NTx (baseline and Months 3, 6, 9, 12, 15, and 18;
enzyme linked immunosorbent assay, ELISA), osteocalcin and dPyr (both
chemiluminescent immunoassay, both at baseline and Months 6, 12, 18) and
OPG (ELISA, at baseline and Months 3, 6, 12, 18) were collected. All sam-
ples were stored at –70ﾰC at a central laboratory facility until batch analyses.
Statistical analyses. The power calculation of the clinical trial has been
described14. Changes in BMD of the LS and dAUC values of measures of
bone metabolism were tested for statistically significant difference between
the 2 treatment groups of patients with 2 sample t tests or Mann-Whitney U
tests, as appropriate. Changes from baseline were tested for statistical signif-
icance with paired t tests or Wilcoxon rank tests, as appropriate. For correla-
tion analyses, using BMD values in both LS and total hip, Spearman correla-
tion coefficients were applied, and for statistical testing of binary variables
between groups, the Fisher exact test. Univariate regression analyses were
applied to explore whether changes in BMD of the LS (dependent variable)
were predicted by changes in measures of bone metabolism (dAUC values as
independent variables) in either of the 2 treatment groups. Identical analyses
were performed with changes in bone marker during the first study months as
independent variables (changes in serum calcium, NTx, OPG, and PTH after
3 mo and of P1CP, dPyr, and osteocalcin after 6 mo). P values < 0.05 were
considered statistically significant; all tests were 2-sided.
RESULTS
Patient characteristics at baseline for the 2 treatment groups
are shown in Table 1. Details on completers, dropouts, doses
of predniso(lo)ne, adverse effects, and effects on bone have
been described14.
During our study, mean (standard deviation) daily dosage
in prednisolone equivalent in the alendronate and the alfacal-
cidol group was 12 (9) and 11 (7) mg/day, respectively, a sta-
tistically nonsignificant difference; cumulative dosage was
5.9 (3.7) and 5.7 (3.4) g, respectively (p > 0.05).
In the alendronate group, there was an increase of 2.3
(4.6)% (p < 0.001) in BMD of the LS from baseline after 18
months (17 BMD missing), and in the alfacalcidol group a
decrease of 1.9 (5.7)% (p = 0.001), 17 BMD missing; the dif-
ference in change between the 2 groups was 4.2 (5.2)% (p <
0.001)14.
Table 2 shows the changes in the alendronate and alfacal-
cidol group of lumbar BMD in g/cm2 and of dAUC values of
measures of bone metabolism. In the alendronate group com-
pared with the alfacalcidol group, there are statistically signif-
icant differences in changes from baseline with respect to
BMD of the LS (increase vs decrease, respectively), P1CP
(decrease vs increase), osteocalcin (decrease vs increase),
PTH (increase vs decrease), and calcium corrected for albu-
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serum level of PTH > 7 pmol/l (upper limit of normal range 7
pmol/l) in the alendronate group versus 9% in the alfacalcidol
group; at 1 month the percentages were 6% versus 0%, at 2
months 4% versus 0%, at 3 months 8% versus 2%, and at 18
months 25% versus 6%, respectively. These differences were
only statistically significant at 18 months (p = 0.001). During
the whole study, 26 of the 99 patients taking alendronate had,
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Table 2. Changes in lumbar spine bone mineral density (BMD) and in measures of bone metabolism in the 2 groups*.
Change in Alendronate Group p, Change from Baseline Alfacalcidol Group p, Change from Baseline p, Difference Between the 2 Groups
BMD, g/cm2 0.02 (0.05) 0.000002 –0.02 (0.07) 0.001 0.000001
0.03 (–0.002 to 0.05) –0.02 (–0.05 to 0.02)
OPG, pmol/l 0.02 (1.5) 0.08 0.3 (1.2) 0.02 0.15
0.1 (–0.2 to 0.6) 0.3 (–0.2 to 1.0)
P1CP, pmol/l –157 (488) 0.02` 164 (565) 0.007 0.0002
–79 (–457 to 130) 188 (–185 to 423)
Osteocalcin, ng/ml –0.5 (1.7) 0.1 1.3 (2.3) 0.0003 0.00007
–0.1 (–1.6 to 0.7) 1.0 (–0.4 to 2.1)
dPyr, nmol/l –0.1 (35) 0.9 –11 (42) 0.08 0.2
–2 (–16 to 20) –3 (–32 to 15)
NTx, nmol/l –172 (325) 0.000001 –143 (399) 0.0007 0.3
–120 (–202 to –28) –65 (–320 to 68)
PTH, pmol/l 1.1 (1.8) 0.000001 –0.7 (1.6) 0.0006 0.000001
0.9 (0.2 to 2.2) –0.5 (–1.4 to 0.3)
Corrected calcium, –0.04 (0.1) 0.001 0.03 (0.1) 0.03 0.00005
mmol/l –0.03 (–0.1 to 0.02) 0.02 (–0.04 to 0.09)
* Mean [standard deviation (SD)] and median (lower quartile to upper quartile), respectively; change in BMD: change from baseline at 18 months; changes
in measures of bone metabolism; mean (SD) delta area under the curve values, corrected for time. OPG: serum osteoprotegerin, P1CP: serum procollagen
type 1 C-propeptide, osteocalcin: serum osteocalcin, dPyr: fasting urine free deoxypyridinoline, NTx: fasting urine N-terminal crosslinking telopeptide of
type 1 collagen, PTH: serum parathyroid hormone, corrected calcium: serum calcium, corrected for serum albumin. Positive values indicate increase from
baseline and negative values a decrease.
Table 1. Patient characteristics at baseline*
Alendronate, Alfacalcidol,
N = 99** N = 101
Age, yrs:mean (SD), range 60 (14), 20–87 62 (15), 18–84
Sex and menopausal status
Females, no. premenopausal/postmenopausal 7/52 10/55
Male, no. 40 36
Caucasian, no 93 87
Height, cm 169 (10) 169 (9)
Weight, kg 74 (13) 73 (12)
Start dosage prednisone equivalents, mg/day 23 (20) 22 (18)
BMD lumbar spine (L2-L4), g/cm2 1.06 (0.21) 1.09 (0.21)
Patients with vertebral deformity at baseline, no. 6 14
Diagnosis, no.
Rheumatoid arthritis 33 41
Polymyalgia rheumatica 36 36
Other*** 30 24
OPG, pmol/l (normal ≥ 0.5) 4.6 (2.6) 5.0 (2.9)
P1CP, pmol/l (normal, men 870–2340, women 680–2049) 1143 (495) 1166 (575)
Osteocalcin, ng/ml (normal 3.1–13.7) 3.6 (2.4) 3.3 (2.5)
dPyr, nmol/l (normal, men 33–81, women 25–59) 64 (46) 74 (51)
NTx, nmol/l (normal 33–715) 414 (366) 504 (446)
PTH, pmol/l (normal 2–7) 3.5 (2.0) 3.8 (2.2)
Corrected calcium, mmol/l (normal 2.2–2.7) 2.36 (0.11) 2.35 (0.11)
* All means (SD), unless indicated otherwise. OPG: serum osteoprotegerin, P1CP: serum procollagen type 1
C-propeptide, osteocalcin: serum osteocalcin, dPyr: fasting urine free deoxypyridinoline, NTx: fasting urine
N-terminal crosslinking telopeptide of type 1 collagen, PTH: serum parathyroid hormone, corrected calcium:
serum calcium, corrected for serum albumin. ** One patient in the alendronate group withdrew before initiation
of randomized therapy. *** Categories with less than 5 patients totally were grouped into the category “other”.at least once, a serum level of PTH > 7 pmol/l versus 12 of the
101 patients taking alfacalcidol (p < 0.01). To facilitate inter-
pretation, the statistically different changes between the 2
groups in measures of bone metabolism are plotted, on the
individual patient’s level (Figure 1) and as mean changes in
time (Figure 2).
In Table 3, correlations of changes in BMD of LS and total
hip and in the dAUC of measures of bone metabolism for the
alendronate and alfacalcidol group are presented. There are
within both groups positive correlations between the 2 mark-
ers of bone formation osteocalcin and P1CP; the same is
found for the 2 markers of bone resorption dPyr and NTx.
Between PTH and calcium corrected for albumin, correlations
are negative within both groups. Between changes in BMD
and changes in measures of bone metabolism, there are no sta-
tistically significant correlations, with the exception of a neg-
ative correlation in the alendronate group between changes in
total hip BMD and NTx. In accord with the missing correla-
tions, regression analyses showed that changes in measures of
bone metabolism (dAUC values for the whole study period
and changes during the first months of the study) could not
significantly predict changes in BMD of the LS in either the
alendronate or the alfacalcidol group (data not shown). In
addition, in the alendronate group we compared the change in
BMD of the LS in the subgroup of patients with a PTH ≤ 7
pmol/l at all points in time (n = 59, 14 missing BMD) versus
those with a PTH level > 7 pmol/l at any point in time (n = 23,
3 missing BMD). In the former subgroup the BMD increased,
with 2.4 (4.5)% versus 2.1 (4.9)% in the latter subgroup (p =
0.9). In accord with this finding, there was no correlation
between changes in BMD and changes in PTH. Serum levels
of OPG did not differ between the 2 groups at baseline (Table
1), nor did they change statistically significantly following
intervention (Table 2).
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Figure 1. Changes within each individual during the 18 months of measures of bone metabolism that were statistically significantly different between alendronate
group (1) and alfacalcidol group (2). Dots are delta AUC values, one dot for each patient, corrected for time; for p values see Table 2.DISCUSSION
As expected, in the alendronate treated group of patients tak-
ing GC there were decreases in the markers of bone formation
P1CP and osteocalcin and a decrease in the markers of bone
resorption, and increase in lumbar BMD. These changes in
bone markers in the alendronate group indicate decreased
bone resorption and, by the coupling of bone resorption and
bone formation, also decreased bone formation, with a net
positive result on BMD.
In contrast, in the alfacalcidol treated group of patients tak-
ing GC we found increases of P1CP and osteocalcin, indicat-
ing stimulation of bone formation and decreases of dPyr and
NTx, indicating inhibition of bone resorption. This suggests
that bone formation and resorption are uncoupled during treat-
ment with alfacalcidol. In addition to stimulating effect on
bone formation, active vitamin D3 enhances intestinal calcium
absorption, which may lead to a tendency of hypercalcemia,
which results in lower circulating levels of PTH and subse-
quently decrease of markers of bone resorption. As treatment
with alfacalcidol was followed by signs of inhibition of bone
resorption and in addition, in contrast to treatment with alen-
dronate, also signs of stimulation of bone formation, one
would expect a superior effect of alfacalcidol on BMD com-
pared to alendronate. However, we and others observed the
opposite outcome6,14, although results of other studies on alfa-
calcidol were promising13. The effects of alfacalcidol and
alendronate on fractures will be studied during prolonged fol-
lowup of the STOP trial14.
In both groups, although markers of bone metabolism
changed on the group level, as can be expected from the mode
of action of the 2 bone loss-preventing therapies, changes in
BMD could not be predicted by nor were they associated with
changes in biochemical measures, with the exception of a neg-
ative correlation in the alendronate group between changes in
1055 Jacobs, et al: BMD and bone markers
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Figure 2. Percentage change in time during the 18 months of measures of bone metabolism that were statistically significantly different between the alendronate
and alfacalcidol groups; delta AUC values; for p values see Table 2; circle = alendronate group, triangle = alfacalcidol group.total hip BMD and the bone resorption marker NTx. This
association mirrors the increased BMD by decreased bone
resorption in this group. In postmenopausal women with
osteoporosis treated with bisphosphonates, an increase in
OPG serum levels along with reduction of bone resorption
markers predicted gain of BMD16, in contrast to findings in
our study. So for the individual patient in daily clinical prac-
tice who is treated with GC, the value of serial assessment of
measures of bone metabolism seems low.Also, in the absence
of fracture data, BMD seems to be the best surrogate endpoint
for a study in GIOP17.
Limitations in our study that restrict direct interpretation of
associations between changes in measures of bone metabo-
lism and changes in BMD are that all patients used GC and
had a rheumatic disease, both factors that also influence bone
markers. Further, the baseline values of measures of bone
metabolism often were taken when patients were already tak-
ing GC (with a maximum duration of 12 weeks before the
start of the study). It is possible that measures of bone metab-
olism can detect short-term changes (i.e., within weeks) in
bone turnover better than longterm changes. Third, there was
heterogeneity of the group with respect to the rheumatological
diagnoses and patients14.
In the alendronate group, there was a decrease in serum
calcium with concomitant increase in PTH. We do not attrib-
ute these changes to GC use. First, similar changes did not
occur in the alfacalcidol group, although perhaps alfacalcidol
prevented this18. Second, the role of secondary hyperparathy-
roidism in the cause of GIOPis in doubt19; and third, in anoth-
er study, an increase in PTH was also found, albeit only in
nocturnal values20. Bisphosphonate treatment causes an
immediate reduction in bone resorption leading to a reduction
in serum calcium that leads to an increase of PTH. The
increase in the PTH following bisphosphonate therapy is a
response to the change in serum calcium. The hypocalcemic
response to bisphosphonates is occasionally severe, especial-
ly in patients with hypoparathyroidism21. The signs of slight
stimulation of PTH by alendronate in our study occurred in
spite of supplementation with calcium and, if indicated, with
vitamin D3.
For pragmatic reasons we gave a standard calcium supple-
ment of 500 mg daily to patients with a daily dietary calcium
intake < 1000 mg. This dose was generally accepted as ade-
quate in The Netherlands at the time the study was designed,
but could have been too low in some patients. Similarly, the
standard dose of 400 IU of cholecalciferol for participants of
the study with baseline serum 25-OHD levels < 30 nmol/l
could have been too low in some. In patients taking alen-
dronate, increased PTH was not associated with differences in
change in BMD compared with patients without increased
PTH, indicative of a normal calcium homeostasis in these
patients taking standard-dose calcium and vitamin D3 supple-
mentation. However, tailoring the dose of these supplements
to the intake of the individual patient probably is to be pre-
ferred.
In our study, changes in markers of bone metabolism were
more favorable in patients taking GC treated with alfacalcidol
than in those treated with alendronate. Nevertheless, BMD
increased in the alendronate group and decreased in the alfa-
calcidol group. Changes in BMD were in general not predict-
ed by changes in measures of bone metabolism. Alendronate
treatment results in slight secondary hyperparathyroidism that
without calcium and vitamin D3 supplementation could have
been more pronounced, which suggests that adequate calcium
and vitamin D3 supplementation is indicated when alen-
dronate is used or bisphosphonates are used.
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Table 3. Correlation coefficients of changes after 18 months in bone mineral density (BMD) of lumbar spine (left value) and total hip (right value) with
changes in measures of bone metabolism for the alendronate group (upper values) and the alfacalcidol group (lower values)*.
Corrected Calcium PTH NTx dPyr Osteocalcin P1CP OPG
BMD --/-- --/-- --/--0.33 --/-- --/-- --/-- --/--
--/-- --/-- --/-- --/-- --/-- --/-- --/--
OPG --/-- --/-- --/-- --/-- --/-- --/--
--/-- --/-- --/-- --/-- --/-- --/--
P1CP --/-- --/-- --/-- --/-- 0.26/0.26
--/-- --/-- --/-- --/-- 0.32/0.32
Osteocalcin --/-- --/-- --/-- --/--
--/-- --/-- --/-- 0.37/0.37
dPyr --/-- --/-- 0.64/0.64
--/-- --/-- 0.62/0.62
NTx --/-- --/--
--/-- --/--
PTH –0.25/–0.25
–0.36/–0.36
* Corrected calcium: serum calcium, correected for serum albumin, PTH: serum parathyroid hormone, NTx: fasting urine N-terminal crosslinking telopep-
tide of type 1 collagen, dPyr: fasting urine free deoxypyridinoline, osteocalin: serum osteocalcin, P1CP: serum procollagen type 1 C-propeptide, OPG: serum
osteoprotegerin. Change in BMD: 18 month value minus baseline value; changes in measures of bone metabolism: delta area under the curve values;
Spearman correlation coefficients, only coefficients with absolute values ≥ 0.25 are given; |r| ≥ 0.25: p < 0.05, |r| > 0.30: p < 0.01, |r| > 0.60: p < 0.000001.REFERENCES
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